A snapshot of the number of vaccine trials conducted globally between 1997 and 2017.
Number of Vaccines Trials: Then and now
HIV-Specific Neutralizing Antibodies: A guide to targets and candidates
A detailed graphic describing the status of pre-clinical and clinical work around relevant bNAbs today.
Where Does Oral PrEP Fit in to Vaccine and AMP Trials?
A global map showing current efficacy trial countries and their status of PrEP implementation.
Vaccine Approaches in Early-Phase Development
An outline of various approaches to vaccine development that are in earlier phase research, e.g., phase I or II trials; development pathways for these candidates are uncertain at this time.
Vaccines and Antibodies on Efficacy Pathways
A timeline of current efficacy programs for vaccines and antibodies, highlighting the P5 program testing pox-protein candidates, the Janssen program testing mosaic-based candidates, and the AMP studies testing the antibody VRC01.
An Advocate’s Guide to Research Terms in the Post-Placebo Era
In Px Wire, AVAC’s quarterly update on HIV prevention design, we presented this illustration on some new types of biomedical prevention trial design. You’ll find a summary of long-acting PrEP trials, a lexicon of key terms for the “post-placebo era”, and a handy illustration for looking smart while you explain “double-dummy double-blind”.
To download just the graphic, without the accompanying text and lexicon, click here: JPG, PDF. For the lexicon only, click here (PDF).
Regulatory Status of TDF/FTC for PrEP
A global snapshot of the regulatory status of oral PrEP by country. JPEG and PPT versions available here.
Introduction to Long-Acting Injectables
This infographic details the process for developing long-acting injectables for PrEP and Treatment U=U.
Trial Participants by Prevention Research Area, 2015
Given the higher rates of acquisition seen across so-called key populations—members of highly burdened and underserved groups—it is critical to provide access to the research process such that they can participate and reap more immediate benefit of scientific progress. Greater efforts must be made to include key populations in this crucial process for the HIV prevention response to be truly impactful.
Global HIV Prevention R&D Investments by Technology, 2000-2015
In 2015, global funding for HIV prevention R&D declined slightly, from US $1.25 billion in 2014 to US $1.20 billion in 2015. This continues a decade of roughly flat funding. The US public sector remained the largest global contributor at US $850 million, and together with the Bill & Melinda Gates Foundation, the largest philanthropic funder, constituted 81 percent of all funding.